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Abstract
Background: Mitral valve repair is preferred over prosthetic replacement. We surgically repaired mitral valve with
degenerated sclerotic lesion and demonstrated mid-term results.
Methods: Mitral valve plasty (MVP) was performed with several procedures including ring annuloplasty, leaflet
slicing and decalcification.
Results: There were 19 males and 19 females with a mean age of 67 ± 12 y.o (n = 38). All patients were successfully
treated MVP except one case with unrepairable injuries of the thin leaflet. In patients underwent MVP (n= 37), MVP
included ring annuloplasty with a rigid full ring of 32 ± 2 mm (n = 37), leaflet slicing (n= 37), decalcification (n= 15) and
artificial chordae (n= 14). Mitral valve area was statistically enlarged by MVP (1.65 ± 0.57 vs 2.51 ± 0.58 cm2, p < 0.001). Left
atrial diameter was statistically reduced after the operation (55 ± 10 vs 46 ± 9 mm, p < 0.001). Severity of MR and right
ventricular systolic pressure (RVSP) were statistically decreased after the operation (MR; 1.8 ± 1.0 vs 0.7 ± 0.9, p < 0.001,
RVSP; 38 ± 15 vs 30 ± 9 mm Hg, p < 0.001). There were 4 cases with residual MR (Grade II, n = 3; Grade III, n = 1). The 30-
days mortality was 0 %. There was one late death due to non-cardiogenic cause (the 3-year survival rate of 97 %) and no
redo case due to deterioration of the mitral valve during follow-up period of 21 ± 13 months.
Conclusions: Successful mid-term survival and freedom from reoperation might expect to the durability of MVP in patients
with mitral sclerotic lesion.
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Background
Rheumatic heart disease is one of degenerative valvular
disorders, which mainly affect mitral valve in the young
population [1]. Although mitral regurgitation (MR) was
the most common lesion in the first and second decades,
the relative prevalence of mitral stenosis (MS) increased
with age [2]. The characteristic alteration is thickening
of the leaflet secondary to inflammation, which results
in sclerotic lesion including atherosclerotic calcification
in the advanced cases [3]. Although the clinical presen-
tation depends on the degenerative lesions such as MR,
and MS and a mixed form, the definitive treatment is
surgical correction despite age. According to earlier sur-
gical reports, the superiority of mitral valve plasty
(MVP) over mitral valve replacement (MVR) had been
already established in patients with MR [4, 5]. However,
MVP for sclerotic lesion is still challenging and the dur-
ability of the procedure had not been established.
Following earlier reports [6, 7], we have surgically treated
patients with mitral sclerotic lesion. We retrospectively
evaluated early and mid-term outcomes of MVP, and
discussed details of technical pitfalls for such patients.
Methods
Patients
Between July 2011 and December 2014, patients with mitral
sclerotic lesion treated by MVP were involved in this series.
This study was approved by the Institutional Review Board
of Tokyo Metropolitan Hiroo Hospital and informed
consent was preoperatively obtained from all patients.
Surgical indication
MVP was the first choice of procedures for mitral scler-
otic lesion. However, we abandoned MVP for limited
cases such as severe diffuse calcification of both mitral
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leaflets and mitral annular calcification (MAC). For lim-
ited cases requiring longer ACC time for MVP
(>60 min), MVP was abandoned and converted to MVR
during operation.
Assessment of valvular morphology and functional
parameters
Trans-thoracic echocardiography was used to evaluate
functional and geometric parameters, including mitral
valvular area (MVA), LV end-diastolic and -systolic
diameter (LVEDD and LVESD), left atrial diameter
(LAD), ejection fraction (EF), right ventricular systolic
pressure (RVSP), and severity of MR and tricuspid re-
gurgitation (TR).
Surgical procedures
Briefly, after cardioplegic cardiac arrest, the LA was
opened via right-sided left atriotomy. MVP was
performed via the right-sided left atriotomy. MVP
included combined mitral procedures such as ring
annuloplasty, leaflet slicing, decalcification, artificial
chordae and chordal cutting, following earlier reports
[6, 7].
White excess membrane on the mitral leaflet was
sharply sliced and bluntly dissected from the clear zone
extending to the rough zone. It was removed to obtain
flexibility of the sclerotic leaflets. Especially for advanced
cases with atherosclerotic calcification, it was crushed by
the Pean Forceps into small pieces, which were manually
removed. After removal of calcification on the leaflet,
thin fragile leaflet appeared beneath calcification. When
the injuries of the mitral leaflet occurred, the tears were
directly closed with polypropylene sutures. For cases
with chordal shortening, it was cut to adjust the height
of coaptation by artificial chordae with expanded poly-
tetrafluoroethylene sutures (GORE-TEX CV-5; W. L.
Gore & Associates, Inc, Flagstaff, Ariz). When the
seagull sign was detected by preoperative echocardiog-
raphy due to chordal shortening, the second chordae of
both leaflets was cut to facilitate valvular mobility. The
mitral orifice was enlarged with these techniques to
pass the Hegar (25 mm in diameter). After mitral valvu-
lar procedures, ring annuloplasty was performed with a
rigid full ring. For patients with Af, MAZE operation
and closure of the LA appendage were concomitantly
performed.
Statistical analysis
Results are expressed as means ± SEM. An analysis was
performed by paired Student’s t test to compare the data.
The Kaplan-Meier survival method was used to calculate
estimates for mid-term survival. The criterion for statis-
tical significance was set at a value of p < 0.05.
Results
There were 19 males and 19 females in this study
(n = 38). The mean age was 67 ± 12 y.o, ranging from
25 to 89 y.o. All patients were Japanese (>50 y.o.)
except two foreign patients (Nepalese 25 y.o., Iranian
49 y.o.). There were 31 patients with chronic or par-
oxymal atrial fibrillation (Af ). There were 5 redo
cases after mitral procedure, including open mitral
commissurotomy (OMC; n = 2), closed mitral com-
missurotomy (CMC; n = 1), and percutaneous trans-
venous mitral commissurotomy (PTMC; n = 2).
All patients were successfully treated by MVP except
one case with unrepairable injuries of the thin leaflet
during operation. MVP was performed with various pro-
cedures including ring annuloplasty (n = 37), leaflet sli-
cing (n = 37), decalcification (n = 15), artificial chordae
(n = 14) and chordal cutting (n = 8). The ring size was
32 ± 2 mm, ranging from 28 to 34 mm. Concomitant
procedures other than MVP included aortic valve re-
placement/plasty (AVR/AVP; n = 10/2), tricuspid annulo-
plasty (TAP; n = 26), MAZE operation (n = 24) and
coronary artery bypass grafting (CABG; n = 3). In a total
of 31 patients with Af, MAZE procedure was underwent
in 24 cases and regular sinus rhythm was obtained in 16
cases (67 %). Aortic cross-clamping (ACC) and cardio-
pulmonary bypass (CPB) time were 131 ± 28 and 152 ±
31 min, respectively.
Echocardiographic parameters were summarized in
Table 1. MVA was statistically enlarged by combined
mitral valve procedures (1.65 ± 0.57 vs 2.51 ±
0.58 cm2, p < 0.001) and LAD was statistically reduced
after the operation (55 ± 10 vs 46 ± 9 mm, p < 0.001).
Severity of MR and RVSP were statistically decreased after
the operation (MR; 1.8 ± 1.0 vs 0.7 ± 0.9, p < 0.001, RVSP;
38 ± 15 vs 30 ± 9 mm Hg, p < 0.001). However, there were
4 cases with residual MR (Grade II, n = 3; Grade III, n = 1)
in this series.
Macroscopic appearances of the mitral leaflets were
shown in Fig. 1. Both mitral leaflets were thick in all
cases (n = 38), and atherosclerotic calcification was de-
tected in advanced cases (n = 15). Sclerotic lesion was
surgically repaired with various procedures described
above and deeper coaptation zone with thin mobile
leaflets was created to obtain enlargement of MVA
and to minimize residual MR.
The 30-days mortality was 0 %. However, there was
one late death caused by cholecystitis during follow-
up periods during a mean period of 21 ± 13 months.
There was no case requiring mitral valve surgery due
to deterioration of the mitral valve. As mid-term sur-
gical results, the 3-year survival rate was 97 %. Dur-
ing follow-up, there was one patient with a history of
re-admission due to congestive heart failure (CHF)
caused by residual MR (Grade III) after MVP (2.7 %).
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Disscussion
We have surgically treated patients with mitral sclerotic
lesion using combined various procedures, including
ring annuloplasty, leaflet slicing, decalcification, artificial
chordae and chordal cutting. To obtain larger mitral
orifice, improvement of valvular mobility by slicing and
decalcification is the most important issue for such
patients. As a result, MVA was successfully enlarged by
MVP and, early and mid-term surgical results were satis-
factory. Accordingly, MAP would be one of the surgical
options for patients with mitral sclerotic lesion.
Surgical repair for rheumatic valvular lesion had been
started in the young population more than 20 years ago
and the procedure is still a challenge for cardiac sur-
geons [8, 9]. In the early period of MVP for rheumatic
valvular disease, the primary objective was avoidance of
prosthetic implantation due to unavailability of pros-
thesis for infants and children. Recently, age of patients
underwent MVP was gradually getting older and surgical
candidates for MVP were extending to adult patients,
who avoid warfarization due to expectancy for preg-
nancy or limitation of utilization of prosthesis in the
developing and advanced countries [6, 10]. In regard to
surgical result, MVP for rheumatic mitral valve had a
superior long-term outcome compared with MVR in
patients without commissural fusion [11]. Then, we
challenged MVP in rheumatic mitral pathology and
successfully repaired advanced mitral lesion in Japanese
elder patients. Although the longest follow-up period
was about 44 months after the operation at this time,
mid-term results were acceptable in regard to survival
and freedom from reoperation.
In patients with rheumatic mitral disease, various pro-
cedures such as leaflet slicing and decalcification were
required for successful MVP because the mitral sclerotic
lesion involved various and complex pathologies in both
leaflets. Therefore, we utilized several procedures de-
pending on the lesion to obtain larger MVA. However,
attentions should be paid to prevent one of potential
complications, i.e. residual MR, especially for patients
with severe calcification at the commissure. Because
Table 1 Echocardiographic parameters
Before operation After operation P value
Left ventricular end-diastolic diameter (mm) 51 ± 6 46 ± 7* p < 0.001
Left ventricular end-systolic diameter (mm) 33 ± 7 30 ± 6* p < 0.001
Left atrial diameter (mm) 55 ± 10 46 ± 9* p < 0.001
Mitral valvular area (cm2) 1.65 ± 0.57 2.51 ± 0.58* p < 0.001
Ejection Fraction (%) 65 ± 8 63 ± 10 p = 0.118
Right ventricular systolic pressure (mm Hg) 38 ± 15 30 ± 9* p < 0.001
Severity of mitral regurgitation 1.8 ± 1.0 0.6 ± 0.7* p < 0.001
Values are expressed as means ± SEM
*P < 0.05 vs. Before operation
Fig. 1 Representative appearances of the mitral leaflets before and
after mitral valve plasty. White thick intima was covered with both
mitral leaflets and there was localized calcification in the middle of the
both leaflets and around the postero-median commissure (left). The
thick leaflets became thin and the mobility of the leaflets increased
after leaflet slicing (right) a. Both mitral leaflets included mild
atherosclerotic lesion without commissural fusion b. The antero-
laretal commissure was affected by advanced atherosclerotic
calcification, which extended to the center of both leaflet c. In the most
advanced case, the mitral leaflet around the antero-lateral
commissure seemed to be destroyed by the broad severe atherosclerosis
(left). However, thin mobile mitral leaflets appeared after careful
decalcification and leaflet slicing (right) d
Hirota et al. Journal of Cardiothoracic Surgery  (2016) 11:81 Page 3 of 5
residual MR would be one of the risk factors for intra-
operative conversion to MVR and CHF requiring re-
admission rather than MS. In our series, there were two
cases requiring additional treatments due to residual
MR. One case necessitated conversion to MVR due to
unrepairable injuries of the thin leaflet after slicing dur-
ing operation. Another case with CHF re-admitted for
medical treatment due to postoperative MR around the
commissure, in which aggressive removal of severe calci-
fication had been performed. Careful handling of the
thin leaflet after leaflet slicing would be one of the most
important issues to improve surgical outcome. Addition-
ally, commissurotomy for calcified commissure was not
necessary, because effective MVA was obtained by nat-
ural coaptation by native leaflets after careful decalcifica-
tion and leaflet slicing. Although the leaflet extension is
also one of the effective procedures for rheumatic
degenerative lesion, we had not applied for such fragile
leaflet after leaflet slicing to avoid unintended injuries
[12]. By our surgical strategy, mitral sclerotic lesion
would be repairable even if the extent of calcification
was severe, but localized.
Although we suggested the feasibility of MVP in pa-
tients with sclerotic lesion, there is no golden standard
to select potential candidates for MVP [13]. The major
reason to abandon MVP would be the extent of calcifi-
cation, requiring higher technical difficulties. In case
with several concomitant procedures, operative time for
MVP should be limited to prevent longer ACC time. For
these reasons, severe diffuse (not localized) calcification
on both mitral leaflets was our relative contraindication.
Redo cases following OMC, CMC and PTMC were not
our absolute contraindication and another report also
supported this idea [14]. Actually, we selected patients
by our impression of preoperative echocardigraphic im-
ages and intraoperative findings of the mitral valve. As a
result, MVA of 1.65 ± 0.57 cm2 was surgically repaired in
this series. However, in patient without our indication of
MVP (candidates for MVR), MVA of 1.14 ± 0.33 cm2
was significantly lower compared with this series. Al-
though larger preoperative MVA would be related to
successful outcome for MVP, the most important issue
for selection of procedure would be the distribution of
calcification, i.e., eccentricity of calcification. Thus, MVP
would be feasible for patients with severe localized calci-
fication of both mitral leaflets unless diffuse calcification
of both mitral leaflets creates circular and fixed calcified
orifice such as fish mouth.
There are several limitations to this study. Firstly, dur-
ability of our procedure had not been established because
follow-up period was not long enough. Additionally, our
results were obtained from retrospective analysis of only
38 patients. Further cases and follow-up period were
required to validate data. Secondly, selection of procedure
(MVP vs MVR) depended on our impression by preopera-
tive echocardiographic images and intraoperative findings,
which may include selection bias of procedure and affect
the data. Thirdly, the operative patients in our series were
much elder compared with other reports. For such com-
plicated valvular lesion, MVR might include beneficial
effects on early and long-term survival due to shorter
ACC and CPB time. A randomized controlled trial is
necessary to conclude the superiority of MVP for such
patients.
Conclusion
We surgically repaired rheumatic mitral valve with
advanced degenerative sclerotic lesion with various pro-
cedures. Successful mid-term survival and freedom from
reoperation might expect the durability of MVP.
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